Effect of Pentoxifylline on Anemia in Hemodialysis Patients - Trial NCT05708248
Access comprehensive clinical trial information for NCT05708248 through Pure Global AI's free database. This phase not specified trial is sponsored by Alexandria University and is currently Not yet recruiting. The study focuses on Hemodialysis Complication. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Alexandria University
Timeline & Enrollment
N/A
Feb 01, 2023
Jul 01, 2023
Primary Outcome
Variation in Hemoglobin (Hb) levels,Variation in Hypoxia inducible factor-2 alpha (HIF-2ฮฑ) levels,Variation in Transforming growth factor ฮฒ1 (TGF-ฮฒ1) levels,Variation in erythropoietin stimulating agents' (ESAs) doses,Variation in ESA resistance index (ESA Dose/kg/Week/Hb)
Summary
The primary goal of this clinical trial is to evaluate the promoting effect of pentoxifylline
 on anemia correction in hemodialysis patients, and involvement of the hypoxia-inducible
 factor-2 alpha. While, the secondary aim is to evaluate the effect of pentoxifylline on
 inflammation, hepcidin and other markers of iron homeostasis in these patients. Participants
 in this trial will be selected to be age and sex ratio matched and will be randomly assigned
 into two groups. Patients in group I will receive their regular doses of erythropoietin
 stimulating agents and other routine treatments plus 400 mg pentoxifylline tablets twice
 daily with meals for 6 months. While, patients in group II will receive their regular doses
 of erythropoietin stimulating agents and other routine treatments.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05708248
Non-Device Trial